短时间高温处理下桃芽淀粉和可溶性糖含量变化与自然休眠解除的关系

以6年生曙光油桃为试材,研究40℃、45℃、50℃3个梯度高温短时间处理对花芽和叶芽的存活率、萌芽级数以及淀粉和可溶性糖含量的影响,探讨短时间高温处理对桃芽自然休眠的调控效应。结果表明:随短时间高温处理时期的推迟,处理温度的升高,处理持续时间的延长,短时间高温处理对桃芽自然休眠的解除作用增强。11月30日高温处理中,40℃高温处理对桃芽自然休眠解除呈负调控效应,其萌芽级数和可溶性糖含量均低于对照,而淀粉含量高于对照;45℃和50℃高温处理对桃芽自然休眠解除呈正调控效应,其萌芽级数和可溶性糖含量与对照相比明显升高,而淀粉含量显著降低,虽然部分花芽和叶芽因高温处理而死亡,但是在存活芽中短时间高温对桃芽自然休眠的解除作用明显增强。12月10日高温处理中,40℃高温处理对桃芽自然休眠解除的调控效应不明显,45℃和50℃高温处理和11月30日处理相同,具有正调控效应,只是前者对桃芽自然休眠的解除效果优于后者。不同高温处理桃芽的萌芽级数和淀粉含量及可溶性糖含量之间的相关性分析表明,淀粉含量的降低,可溶性糖含量的升高即淀粉向可溶性糖的快速转变是高温解除休眠的部分原因。     

Cardiac troponin I in canine patients with lymphoma and osteosarcoma receiving doxorubicin: comparison with clinical heart disease in a retrospective analysis

The cumulative cardiotoxicity that occurs as a result of doxorubicin chemotherapy is irreversible and can affect both quality and quantity of life for the cancer patient. Cardiac troponin I (cTnI) is a sensitive and specific marker of cardiomyocyte death. The purpose of this retrospective study was to evaluate serum concentrations of cTnI in dogs with lymphoma or osteosarcoma given doxorubicin chemotherapy, and with known cardiac outcome, based on a minimum assessment by physical examination and thoracic radiography. Serum samples were also available for cTnI measurement from seven healthy dogs given intracoronary doxorubicin. Serial serum samples obtained before, during and after doxorubicin chemotherapy showed increased cTnI concentrations in some clinical patients following chemotherapy (P = 0.0083 compared to baseline), but this did not correlate with clinical signs of cardiomyopathy. In dogs that subsequently developed cardiomyopathy however, serum cTnI concentrations were elevated before clinical signs became evident (confirmed with echocardiography).     

A retrospective review of treatment and response of high‐risk mast cell tumours in dogs

This retrospective case series evaluates survival outcome of 94 dogs with high metastatic risk mast cell tumours (MCT). Patients were treated with a cytotoxic chemotherapy protocol or the tyrosine kinase inhibitor masitinib, in the presence of gross disease or as an adjunct to surgical resection of the primary tumour. In patients presenting with metastatic disease, surgical resection of the primary tumour with adjunctive therapy with any chemotherapy incurred a significant survival advantage [median survival time (MST): 278 days] compared to patients receiving chemotherapy without surgical excision of the primary tumour (MST: 91 days, P < 0.0001). Patients with a surgically excised Patnaik grade II tumour and high Ki‐67 in the absence of metastatic disease treated with vinblastine and prednisolone showed a significantly longer survival (MST: 1946 days) than those treated with masitinib (MST: 369 days, P = 0.0037). Further prospective case‐controlled clinical trials of high‐risk MCTs are required to make precise evidence‐based treatment decisions for individual patients.     

Fractionated oral dosing and its effect on cyclophosphamide pharmacokinetics in dogs with high-grade multicentric lymphoma

Cyclophosphamide (CP) is an alkylating agent commonly included in multi-drug treatment protocols for canine cancer. As a prodrug, CP requires hepatic metabolism for activation to the intermediate compound 4-hydroxycyclophosphamide (4-OHCP) which then spontaneously forms alkylating phosphoramide mustard. CP is frequently administered in a fractionated manner, with the total dose given over multiple days. CP is reported to cause auto-induction of metabolism in humans, with faster CP clearance and relatively increased 4-OHCP formation following fractionated versus bolus dosing, however canine pharmacokinetic studies of CP dose fractionation are lacking. The study objective was to evaluate the pharmacokinetics of fractionated oral CP dosing at a dose of 200–250 mg/m² over 3 to 4 days in a prospectively identified population of cancer-bearing dogs. Plasma concentrations of CP and 4-OHCP were measured by ultra-high performance liquid chromatography tandem-mass spectrometry in eight dogs following the first and last doses to assess for auto-induction of CP metabolism. No significant difference in the rate of CP elimination between first and last doses were detected (0.73 ± 0.46 vs. 1.22 ± 0.5 h⁻¹; p = .125). Additionally, no significant difference in dose-normalized 4-OHCP exposure was identified between first and last doses (5.9 ± 2.1 vs. 7.9 ± 6.4 h × ng/ml; p = .936). These results suggest that fractionated dosing may not increase exposure to the active metabolite of CP in dogs as it does in humans. As such, standard bolus dosing and fractionated dosing may be equivalent in terms of bio-activation of CP in dogs administered a dose of 200–250 mg/m².     

Evaluation of mechlorethamine,vinblastine, procarbazine,and prednisone for the treatment of resistant multicentric canine lymphoma

Multi-agent chemotherapy successfully induces remission in most naïve, high-grade canine lymphoma patients; however, disease recurrence is common. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) is an effective rescue protocol used to re-induce remission, but is associated with gastrointestinal toxicity and can be a less desirable option for patients that previously failed vincristine-containing protocols. Therefore, alternative members of the vinca alkaloid family, such as vinblastine, could be potentially advantageous as substitutes for vincristine to reduce gastrointestinal toxicity and chemoresistance. The objective of this study was to report the clinical outcomes and toxicity of 36 dogs with relapsed or refractory multicentric lymphoma treated with a modified MOPP protocol whereby vincristine was replaced with vinblastine (MVPP). The overall response rate to MVPP was 25% with a median progression free survival of 15 days and a median overall survival of 45 days. MVPP at the prescribed doses resulted in modest and transient clinical benefit, but was well tolerated with no treatment delays or hospitalizations secondary to side effects. Given the minimal toxicity, dose intensification could be considered to improve clinical responses.     

Use of intralesional cisplatin to successfully treat distal limb haemangiosarcoma in a foal

A 4-month old, 200 kg, grey warmblood colt presented for a firm, non painful mass on the distal medial aspect of the left third metatarsus. Excisional biopsy revealed a diagnosis of haemangiosarcoma. Equine haemangiosarcoma is uncommon and only limited reports of successful treatment are available. The prognosis for survival is therefore considered to be poor. After two separate incidences of recurrence with incomplete excision of the tumour, intralesional treatment with cisplatin without excision or debulking was performed on three separate occasions. Intralesional cisplatin injection was performed at monthly intervals for three treatments. Four years post treatment with cisplatin, the horse remained in remission. This case report describes the diagnostic and treatment challenges for successful treatment of a primary haemangiosarcoma on the distal limb of a warmblood foal using intralesional cisplatin chemotherapy.     

冬季低水温鳜短期饥饿和摄食的生理状态比较

为比较鳜短期饥饿与摄食的生理状态,实验以我国鳜主产区广东省的冬季水温为参照,在(13±1)°C的水温条件下,选取体质量为(84.13±0.14) g的鳜90尾,分为饥饿组(饥饿15 d)和摄食组(摄食15 d),实验结束后测定各项理化指标。结果显示：(1)摄食组鳜的体质量、肝糖原、全鱼与肌肉的粗蛋白、粗脂肪含量均显著高于饥饿组,摄食组增重7.54%,而饥饿组减重8.39%。(2)摄食组鳜血浆谷丙转氨酶和谷草转氨酶活性显著低于饥饿组,但甘油三酯含量显著高于饥饿组,各类血细胞数量与血糖水平则无明显差异。(3)摄食组鳜的消化酶活性显著高于饥饿组,肠道组织结构发育更好。(4)摄食组鳜肝脏抗氧化能力显著高于饥饿组,且饥饿组部分肝细胞有明显的结构损伤,脂滴数量显著少于摄食组。(5)摄食组鳜的血浆溶菌酶活性和血浆、脾脏、肾脏免疫球蛋白M含量显著高于饥饿组。(6)摄食组与饥饿组鳜背肌氨基酸组成无显著差异。但脂肪酸组成有显著差异,摄食组鳜背肌饱和脂肪酸与单不饱和脂肪酸总量显著低于饥饿组,而多不饱和脂肪酸与高不饱和脂肪酸总量显著高于饥饿组。研究表明,在本实验条件下,摄食组增重而饥饿组减重,两种处理增重量差...     

短学期制下植物学实验课程开设探索

介绍了短学期制下植物学实验课程概况,指出了课程开设面临的问题,提出了相应的解决对策与建议。     

Ethnoveterinary Medicine in the Northern Provinces of Cameroon

Veterinary Research Communications -